Bioventix PLC

LSE BVXP.L

Bioventix PLC Operating Cash Flow for the year ending June 30, 2024: USD 10.82 M

Bioventix PLC Operating Cash Flow is USD 10.82 M for the year ending June 30, 2024, a 7.82% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Bioventix PLC Operating Cash Flow for the year ending June 30, 2023 was USD 10.03 M, a 8.96% change year over year.
Bioventix PLC Operating Cash Flow for the year ending June 30, 2022 was USD 9.21 M, a 4.55% change year over year.
Bioventix PLC Operating Cash Flow for the year ending June 30, 2021 was USD 8.81 M, a -8.06% change year over year.
Bioventix PLC Operating Cash Flow for the year ending June 30, 2020 was USD 9.58 M, a 28.36% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

LSE: BVXP.L

Bioventix PLC

CEO	Mr. Peter John Harrison MA
IPO Date	April 29, 2014
Location	United Kingdom
Headquarters	27–28 Eastcastle Street
Employees	12
Sector	Healthcare
Industries Biotechnology 3D Printing Cosmetics Personal Care Pet Food Pharmaceuticals

Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

Key trends

Past 5 years